ОбзорГрафикНовостиTraderScreen

Soc. Generale Call 25 SDZ 20.06.2.../  DE000SW8Q6N4  /

Frankfurt Zert./SG
11.11.2024  21:47:51 Изменение+0.050 Бид11.11.2024 Предложение11.11.2024 Базовый актив Цена исполнения Дата истечения Тип опциона
1.650EUR +3.13% 1.650
Величина цены спроса: 4,000		 1.730
Величина цены предложения: 4,000		 SANDOZ GROUP N 25.00 CHF 20.06.2025 Call
GlobeNewswire 12.08 Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire 08.08 Sandoz reports second-quarter sales and half-year 2024 results
GlobeNewswire 25.07 Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory dise...
GlobeNewswire 01.07 FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
GlobeNewswire 22.05 Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire 07.05 Sandoz reports first quarter 2024 sales
GlobeNewswire 30.04 Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire 30.04 Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire 22.04 Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire 21.03 Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...
GlobeNewswire 13.03 Sandoz reports fourth quarter 2023 sales and full-year 2023 results
GlobeNewswire 05.03 Sandoz receives FDA approval for first and only denosumab biosimilars
GlobeNewswire 05.03 Sandoz announces nominations to the Board of Directors and leadership change
GlobeNewswire 04.03 Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire 29.02 Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser ...
GlobeNewswire 01.02 Sandoz announces changes in the Board of Directors
GlobeNewswire 31.01 Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
GlobeNewswire 22.01 Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire 21.11.2023 Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve pa...
GlobeNewswire 10.11.2023 Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center ...
GlobeNewswire 08.11.2023 Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds
GlobeNewswire 26.10.2023 Sandoz successfully issues CHF 750 million in inaugural bonds
GlobeNewswire 24.10.2023 Sandoz reports year-to-date sales for the first nine months of 2023
GlobeNewswire 04.10.2023 OTC Markets Group Welcomes Sandoz Group AG to OTCQX
TeleTrader 04.10.2023 Sandoz seals spin-off from Novartis, starts trading